AULSF (Austar Lifesciences) ROCE %: 5.00% (As of Dec. 2025)


AULSF Austar Lifesciences Ltd AULSF
49 GF Score
Price $0.07
GF Value $0.10
! 6 Warning Signs
View Full Analysis

What is Austar Lifesciences ROCE %?

Austar Lifesciences AULSF 49 ROCE % is 5.00% as of Dec. 2025. GuruFocus rates AULSF with a GF Score™ of 49/100 and a GF Value™ of $0.10. The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Austar Lifesciences's annualized ROCE % for the quarter that ended in Dec. 2025 was 5.00%.

Austar Lifesciences  (OTCPK:AULSF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Austar Lifesciences ROCE % Related Terms

Austar Lifesciences ROCE % Historical Data

* Premium members only.

The historical data trend for Austar Lifesciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Austar Lifesciences ROCE % Chart

Austar Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.13 12.76 -1.99 4.05 6.67

Austar Lifesciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.26 3.80 4.31 8.16 5.00
AULSF
49GF Score
Austar Lifesciences Ltd AULSF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Austar Lifesciences ROCE % Calculation

Austar Lifesciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=8.553/( ( (286.186 - 163.265) + (302.136 - 168.684) )/ 2 )
=8.553/( (122.921+133.452)/ 2 )
=8.553/128.1865
=6.67 %

Austar Lifesciences's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=6.586/( ( (282.489 - 152.651) + (302.136 - 168.684) )/ 2 )
=6.586/( ( 129.838 + 133.452 )/ 2 )
=6.586/131.645
=5.00 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 5.00% mean?
Austar Lifesciences (AULSF) has a ROCE % of 5.00% as of Dec. 2025.
Is Austar Lifesciences' ROCE % too high?
Austar Lifesciences' current ROCE % is 5.00%. The Medical Devices & Instruments industry median ROCE % is 2.23. Austar Lifesciences' value of 5.00% is 124.2% above this industry median. Overall, Austar Lifesciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' ROCE % compare to ABT and SYK?
Austar Lifesciences' ROCE % of 5.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Austar Lifesciences' value of 5.00% is 124.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current ROCE % of 5.00% is 124.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current ROCE % is 5.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current ROCE % of 5.00%. The stock's GF Value™ is $0.10, compared to a current price of $0.07 — trading 30% below its estimated fair value. The current ROCE % is 5.00% and 124.2% above the Medical Devices & Instruments industry median of 2.23. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current ROCE % is 5.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Austar Lifesciences (AULSF) Overvalued in 2026?

Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued. The current stock price of $0.07 is trading 30% below its estimated GF Value™ of $0.10.

Key valuation signals for AULSF:

  • ROCE %: 5.00%
  • GF Value™: $0.10 vs. price of $0.07 (30% below fair value)
  • GF Score™: 49/100 with 6 warning signs
  • Industry Position: 124.2% above the Medical Devices & Instruments median

No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Austar Lifesciences Business Description

Other Exchanges 06118:Hong Kong
Address No.1018 Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score

Get the complete analysis for AULSF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.07
Price
$0.10
GF Value